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Table 1
Risk Factor Univariable
n HR 95% CI P value
Before Onset
Age at HCT, y
18-40 29 Ref
41-55 70 1.8 0.5-6.4 0.3
> 55 59 2.3 0.7-8.05 0.2
Related donor 79 0.6 0.3-1.2 0.2
Reduced Intensity Conditioning 51 1.1 0.5-2.4 0.7
History of aGVHD III-IV 20 4.0 1.9-8.5 < .001
Onset
Karnofsky Performance Score  70% 31 4.6 2.5-9.5 < .001
NIH Onset Severity
Mild 23 Ref
Moderate 79 0.6 0.2-1.8 0.4
Severe 56 1.2 0.4-3.4 0.7
Progressive onset vs De novo/Quiescent 34 2.1 1.0-4.5 0.05
Platelets < 100,000/mm3 at onset 42 1.4 0.7-3.1 0.3
On steroids at onset 28 2.0 0.9-4.5 0.09
NIH grade 1 liver at onset 40 0.3 0.1-0.9 0.03
NIH grade 2/3 lung at onset 17 3.3 1.03-
10.3
0.04
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Chronic GVHD (cGVHD) is the most important long-term
complication of allogeneic transplantation (HCT). It evolves
from immune-mediated inﬂammation to ﬁbrogenesis,
resulting in end organ damage such as sclerotic skin and
bronchiolitis obliterans syndrome. Thus, biomarkers of
extracellular matrix (ECM) remodeling and ﬁbrosis may
provide insight into the biology of the disease and contribute
to diagnosis and outcome prediction. In order to identify
promising candidates, we conducted a discovery experiment
in 112 adult patients (median age 52.5 y, range 18-68) with
new onset cGVHD. Median time to onset of cGVHD was 165
d (range 37-547) post-HCT. Overall NIH severity at onset was
mild (n¼16, 14%), moderate (n¼53, 47%) or severe (n¼43,
39%). Themajority of patients had at least one overlap feature
(elevated liver enzymes, erythematous rash or GI symptoms;
80%). Plasma samples were obtained at the time of cGVHD
onset, biomarkers were assayed simultaneously using a lab-
derived (non-commercial) Luminex bead-based assay, and
levels of each analyte (assessed by deciles) that provided the
best discriminationwith survivalweredetermined. Levels of 3
proﬁbrotic proteins (CCL2, IGF-1, IL-13Ra) signiﬁcantly
correlated with TGF-b levels. Of these, TGF-b provided the
strongest associationwith outcomes 1 y post-onset of cGVHD.
Patients with low TGF-b ( 10 pg/ml; n¼36) were 3 times
more likely to relapse (Cumulative Incidence (CI) 17%vs5%,P¼
.05) and4 timesmore likely to experienceNRM(CI 23%vs 5%,P
¼ .01) than patients with high TGF-b (> 10 pg/ml; n¼76).
These increases resulted in lower progression free survival
(PFS 60% vs 89%,P¼ .001) andoverall survival (OS 72% vs 92%,P
¼ .01). Low TGF-b was also signiﬁcantly correlated with the
following features at onset: low performance status (P ¼ .01),
platelet< 100K (P¼ .01), and NIH lung 2/3 (P¼ .01). However,
the impact of low TGF-b on OS and PFS was independent of
eachof these factorswhenassessed inbivariateanalysis. There
was no correlationwith TGF-b levels and other characteristics
such as patient age, diagnosis, high risk disease at HCT, donor
type, overallNIHscoreorprogressiveonset cGVHD.Patients in
thehigh TGF-b group andhigh IL-13 group (>200pg/ml)were
more likely to later develop sclerotic skin (n¼20) (TGF-b 80%
vs 65%,P¼ .1; IL-1385%vs 62%,p¼0.04). On theotherhand, low
levelMMP2(5000pg/ml), anantiﬁbroticmetalloproteinase,
were more likely to develop sclerotic cGVHD (50% vs 21%,P ¼
.007). These results suggest ECM turnover is active at the time
of cGVHD onset, even prior to the development of clinically
apparent sclerosis. Further investigationof factors that impact
the balance and transition between inﬂammation andﬁbrosis
may provide a better understanding of the pathophysiology
and new biomarker opportunities for cGVHD.
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Chronic graft versus host disease (cGVHD) is a major contrib-
utor to morbidity and mortality in long-term survivors of
allogeneic hematopoietic cell transplantation (HCT). The
treatment course is heterogeneous and unpredictable, and
a prognostic system at the time of disease onset is highly
desirable. We developed a simple system that should mini-
mize inter-provider variability, and can be applied at disease
onset.We studied 341 consecutive adult patients (age 18-71y;
median 53y) who received HCT at the University of Michigan
from 2007 to 2010. Datawas prospectively collected under an
IRB approved protocol. Cumulative incidence of cGVHD was
47%, with amedian time to onset of 190d (range 37-806d).We
performed univariable analysis on multiple potential risk
factors (RF) for non-relapse mortality (NRM), with relapse as
a competing risk (Table 1). History of severe acute GVHD
grades III/IV (severeaGVHD) (HazardRatio (HR)¼4.0,P< .001),
Karnofsky performance score (KPS)  70% (HR 4.6, P < .001),
and grade 2/3 lung (HR¼3.3,P ¼ .04) were the strongest
predictors of NRM,while presence of grade 1 liver cGVHDwas
protective (HR¼0.3,P ¼ .03). The simplest stratiﬁcation
grouped patients into 3 categories: High risk (KPS 70% and/
or severe aGVHD), low risk (grade 1 liver, without high risk
features), and intermediate risk (all others). Four year NRM in
our model was 52% in high risk (n¼44, ref), 4% in low risk
(n¼28,P ¼ .01), and 18% in intermediate patients (n¼86,P ¼
.001). Within the high risk group, both low KPS and prior
severe aGVHD remained independent predictors after
adjustment for eachother (HR¼4.5,P¼ .02 andHR¼3.4,P¼ .02,
respectively), and in the entire cohort. Low KPS patients were
more likely to have lung involvement, be on steroids, andhave
more severe cGVHD, implying that KPS serves as a composite
of multiple other RF, including both HCT-related morbidities
and cGVHD burden. In addition to KPS and history of severe
acute GVHD, lack of response 1 month after the initiation of
therapy was independently predictive of NRM in 141 treated
patients (HR¼ 3.1, 95% CI 1.3-7.4, P < .01). If validated in an
independent population, this classiﬁcation system may be
clinically useful and facilitate referral and management in
chronic GVHD clinics.
